• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

New migraine options needed

Article

The American Migraine Prevalence and Prevention (AMPP) Study recommends new options for those with cardiovascular event histories who also need migraine treatment

Almost 5 million Americans with episodic migraine (EM) should not be prescribed a triptan, the only class of acute medications FDA approved and developed for migraine, because of the presence of cardiovascular contraindications, according to results from the American Migraine Prevalence and Prevention (AMPP) study.

The results of the study were presented in June at the 2013 International Headache Congress in Boston.

 “Triptans are widely prescribed and effective; however their use is contraindicated with persons with cardiovascular [CV] event histories and conditions,” according to Dawn Buse, PhD, associate professor of neurology, Albert Einstein College of Medicine, Montefiore Headache Center, New York City. “This leaves a substantial number of individuals without safe and effective treatment for migraine. Awareness of this unmet need and the resulting need for safe and effective therapies for this large group of patients is vital to the effective care of persons with migraine.”

The study analyzed 6,723 patients with EM.

CV Events and Procedures

Aged <40

Aged 40-59

Aged ≥60

Myocardial Infarction

6 (0.4%)

112 (3.4%)

104 (8%)

TIA

17 (1.2%)

135 (3.9%)

101 (7.2%)

Stroke

11 (0.8%)

72 (2.1%)

76 (5.4%)

Claudication

85 (6.2%)

294 (8.6%)

182 (13.1%)

Angina

58 (4.2%)

271 (7.9%)

192 (13.7%)

Coronary Bypass Surgery

11 (0.8%)

41 (1.1%)

49 (3.2%)

Coronary Angioplasty/Stenting

15 (1.0%)

114 (3.1%)

100 (6.5%)

Carotid Artery Surgery/Stenting

10 (0.7%)

28 (0.8%)

22 (1.4%)

Peripheral Artery Bypass Surgery

10 (0.7%)

32 (0.9%)

16 (1%)

Respondents with ≥1 Event/Procedure

151 (11.1%)

623 (18.7%)

460 (33.6%)

 

 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.